Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 543-549

  Slattery, John T ^a,b   Risler, Linda J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bone marrow transplantation; Busulfan; Graft rejection; Pharmacokinetics; Relapse; Toxicity; Venocclusive disease

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ADULT; AREA UNDER THE CURVE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; ELECTROCHEMICAL DETECTION; FEMALE; GAS CHROMATOGRAPHY; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LIVER VEIN OBSTRUCTION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; TRANSPLANTATION CONDITIONING;

EID: 0031711811     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00017     Document Type: Conference Paper

References (21)

1. Grochow LB. The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993;20(suppl 4):18-25.
2. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls. Anticancer Res 1994;14:2363-70.
3. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
4. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-60.
5. Roberts JJ, Warwick GP. The mode of action of alkylating agents-III: the formation of 3-hydroxytetrahydrothiophene-1:1-dioxide from 1:4-dimethanesulphonyloxybutane (myleran), S-β-L-alanyl-tetrahydrothiophenium mesylate, tetrahydrothiophene and tetrahydrothiophene-1:1-dioxide in the rat, rabbit, and mouse. Biochem Pharmacol 1961;6:217-77.
6. 14C-busulfan in isolated perfused rate liver. Eur J Drug Metab Pharmacokinet 1987;45: 71-6.
7. Marchand DH, Remmel RP, Abdel-Monem MM. Biliary excretion of a gluthatione conjugate of busulfan and 1,4-dibromobutane in the rat. Drug Metab Dispos 1988;16:85-92.
8. Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat. Drug Metab Dispos 1987;15:399-402.
9. Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busuiphan is adults. Eur J Clin Pharmacol 1989;36:525-30.
10. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferase α, μ, and π. Drug Metab Dispos 1996; 24:1015-9.
11. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997;57:5509-16.
12. Tutschka PJ, Santos GW. Bone marrow transplantation in the busulfan-treated rat, II: effect of cyclophosphamide and antithymec serum on the presensitized state. Transplantation 1975;20:116-22.
13. Tutschka PJ, Santos GW. Bone marrow transplantation in the busulfan-treated rat, III: relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. Transplantation 1977;24:52-62.
14. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-53.
15. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118: 255-67.
16. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17:225-30.
17. Demirer T, Buckner CD, Applebaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation or autologenous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996;17: 491-5.
18. Demirer T, Buckner CD, Applebaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation or allogeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996;17:341-6.
19. Gibbs JP, Yang JS, Slattery JT. Comparison of human liver and small intestinal glutathione 5-transferase-catalyzed busulfan conjugation in vitro. Drug Metab Dispos 1998;26:52-5.
20. Hassan M, Ljungman P, Bolme, et al. Busulfan bioavailability. Blood 1994;84:2144-50.
21. Vassal G, Re M, Gouyette A. Gas chromatographic-mass spectrometry assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr 1988;428:357-61.